What We Know About the Effect of Psychotropic Drugs on Migrant Kids
A federal judge on Monday ruled that the government must obtain parental or guardian consent before administering psychotropic drugs—those that can affect the brain or behavior—to migrant children in its care. But plenty of questions still remain about what these drugs do to young brains in the first place.
“The benefits or risks of psychotropic medications to brain development are only beginning to be evaluated,” says Dr. Manpreet Singh, director of the Pediatric Mood Disorders Program at Stanford University. “We haven’t actually looked, directly and in systematic ways, at the effects o...
Source: TIME: Health - July 31, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime onetime Source Type: news
Antipsychotic Tx Linked to Adiposity Changes in Youths
THURSDAY, June 14, 2018 -- Youth receiving antipsychotic treatment have adverse changes in adiposity and insulin sensitivity, with the greatest fat increases seen with olanzapine, according to a study published online June 13 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news
Some Antipsychotics in Pregnancy May Up Gestational Diabetes Risk
(MedPage Today) -- Elevated risk seen with continuing olanzapine, quetiapine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 8, 2018 Category: Cardiology Source Type: news
Two Antipsychotics Linked to Risk for Gestational Diabetes Two Antipsychotics Linked to Risk for Gestational Diabetes
Two antipsychotics, quetiapine and olanzapine, have been linked to an increased risk for gestational diabetes in women who continue to take these drugs during pregnancy, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news
The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s, recently divorc...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news
Lowering Antipsychotic Dose Can Improve Symptoms in Schizophrenia Lowering Antipsychotic Dose Can Improve Symptoms in Schizophrenia
Reducing the dose of risperidone and olanzapine can improve cognitive function and negative symptoms in patients with stable schizophrenia, new research from China suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 27, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Medicating for mental health
Weight gain and Type 2 diabetes are potential side effects in people taking a common medication to treat mental illness. Now a new University of Guelph study has revealed that a single bout of intense exercise performed right before taking a dose of olanzapine could be a way to prevent these side effects. (Source: World Pharma News)
Source: World Pharma News - March 21, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Medicating for mental health
(University of Guelph) University of Guelph researchers found evidence that a single bout of exhaustive exercise protects against acute olanzapine-induced hyperglycemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2018 Category: International Medicine & Public Health Source Type: news
FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)
[03-23-2015] The U.S. Food and Drug Administration (FDA) has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Olanzapine Has Lower Benefit-to-Risk Ratio in Less Severe Bipolar I Olanzapine Has Lower Benefit-to-Risk Ratio in Less Severe Bipolar I
Patients with less-severe bipolar I disorder benefit less from olanzapine than do those with more-severe disease, but both groups experience the same side effects, according to a new meta-analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Olanzapine and Fluoxetine (Symbyax) Capsules (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 25, 2017 Category: Drugs & Pharmacology Source Type: news
Antipsychotic Polypharmacy With Risperidone and Olanzapine Antipsychotic Polypharmacy With Risperidone and Olanzapine
Given high rates of treatment failure for initial therapy of schizophrenia, is combining risperidone and olanzapine an appropriate approach to improve clinical response and limit adverse effects?Medscape Pharmacists (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2017 Category: Consumer Health News Tags: Pharmacist Ask the Expert Source Type: news
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Important developments that are addressed by the current update include the antiemetic efficacy of olanzapine; evidence to expand the use of NK1 receptor antagonists; and increasing interest in cannabinoids. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 2, 2017 Category: Consumer Health News Source Type: news
Antipsychotic Added to ASCO Antiemetic Guide
(MedPage Today) -- Olanzapine plus standard three-drug regimen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 1, 2017 Category: Hematology Source Type: news
2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer
The aim of this paper was to develop a set of evidence-based guidelines for the management of different syndromes related to nausea and vomiting in advanced cancer. The authors found that the level of evidence in most studies is low, but conclude that the drug of choice is metoclopramide, with alternative options including haloperidol, levomepromazine, or olanzapine. For bowel obstruction, the recommendation is to use octreotide given alongside an antiemetic (haloperidol) and where octreotide is not an option to use an anticholinergic antisecretory agent. For opioid-induced nausea and vomiting, no recommendation could be m...
Source: Current Awareness Service for Health (CASH) - April 25, 2017 Category: Consumer Health News Source Type: news
